GGrantIndex
← Search

Proteomics Shared Resource

$193,732P30FY2025CANIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Trial NCT06508463Trial NCT06387979Trial NCT06381154Trial NCT06353191Trial NCT06315595Trial NCT06271291Trial NCT06238648Trial NCT06207188Trial NCT06160206Trial NCT06115772Trial NCT06078709Trial NCT06075524Trial NCT06073951Trial NCT06058663Trial NCT05917145Trial NCT05910801Trial NCT05720624Trial NCT05717153Trial NCT05704283Trial NCT05703399Trial NCT05674123Trial NCT05653661Trial NCT05640765Trial NCT05612100Trial NCT05591092Trial NCT05584449Trial NCT05575440Trial NCT05560009Trial NCT05557877Trial NCT05556525Trial NCT05549661Trial NCT05547386Trial NCT05547347Trial NCT05541016Trial NCT05530759Trial NCT05526417Trial NCT05523154Trial NCT05518903Trial NCT05512767Trial NCT05507879Trial NCT05507541Trial NCT05497804Trial NCT05465954Trial NCT05465941Trial NCT05447923Trial NCT05447910Trial NCT05443971Trial NCT05438563Trial NCT05417867Trial NCT05416983Trial NCT05412953Trial NCT05411523Trial NCT05411497Trial NCT05410977Trial NCT05407038Trial NCT05407025Trial NCT05403580Trial NCT05399004Trial NCT05393713Trial NCT05392946Trial NCT05388877Trial NCT05388851Trial NCT05388058Trial NCT05388006Trial NCT05356897Trial NCT05294367Trial NCT05288062Trial NCT05269381Trial NCT05246670Trial NCT05232851Trial NCT05224271Trial NCT05222620Trial NCT05212428Trial NCT05199285Trial NCT05194293Trial NCT05176223Trial NCT05168163Trial NCT05130060Trial NCT05112627Trial NCT05112614Trial NCT05111314Trial NCT05077735Trial NCT05075980Trial NCT05053100Trial NCT05045066Trial NCT05033288Trial NCT05030298Trial NCT05018208Trial NCT05005182Trial NCT04999826Trial NCT04975516Trial NCT04967196Trial NCT04926948Trial NCT04925817Trial NCT04917744Trial NCT04906369Trial NCT04897009Trial NCT04895735Trial NCT04892277Trial NCT04892264

Abstract

PROTEOMICS SHARED RESOURCE: ABSTRACT Characterization and quantitation of proteins at both the single protein and proteome levels are critical to advancing the understanding of cancer biology and to developing novel therapeutic strategies. The Proteomics Shared Resource (PROTSR) at the Mayo Clinic Comprehensive Cancer Center (MCCCC) provides powerful proteomics tools to study a wide range of biomedical questions in cancer. These include biomarker discovery, signaling pathway analysis, and interactome analysis to targeted quantitation of proteins in clinical samples and development of diagnostic assays. With strong support from the Mayo Clinic leadership, Akhilesh Pandey (NTTM, MCR), a pioneer in mass spectrometry and proteomics, was recruited from Johns Hopkins University to Mayo Clinic in 2018. He became the new PROTSR Director in 2020, leading its transformation from offering routine protein characterization services to developing and deploying cutting-edge and novel proteomics techniques for accelerated discoveries by MCCCC investigators. PROTSR proposes three Specific Aims: Aim 1: Provide MCCCC members with key services in protein analysis, proteomics, and mass spectrometry to enhance cancer research activities. Aim 2: Provide MCCCC members with consultation on project planning, experimental design, and data analysis and interpretation, as well as convenient in-house access to all of its services. Aim 3: Evaluate and implement advanced instrumentation and novel technologies to enhance current services and to support the implementation of new service lines. The PROTSR, composed of 14 faculty and staff, offers nine service lines. Most proteomics services are performed using various mass spectrometry-based LC/MS-MS systems. These include gel-band ID, label-free quantitative proteomics using data-dependent or data-independent acquisition and tandem mass tag-based quantitative proteomics. Additional services include the analysis of post-translational modifications, including global phosphoproteomics and analysis of antibody enrichment–based acetylome, ubiquitylome, methylome, and tyrosine phosphoproteome. Recently, three new service lines have been introduced: targeted analysis using multiple reaction monitoring, single-cell proteomics, and spatial proteomics via laser capture microdissection. In addition, the PROTSR offers proteomics services on non-MS platforms, including single-cell secretome and signaling analysis on the IsoSpark platform, the Olink HT Platform for measuring about 5,300 proteins using Proximity Extension Assay technology with next-generation sequencing (NGS) readouts and peptide synthesis and peptide microarrays. 40% of revenue in the current funding period has come from MCCCC members. Member Utilization 2019-2023: 108 Total (1 CPCS, 4 REDI, 26 CGSM, 30 CII, 26 NTTM, 21 ACTS) Publication by Members: 26, 8 with Impact Factor >10

View original record on NIH RePORTER →